Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of BMN 701 in patients with Pompe disease
2011-001805-28Phase 2Completed
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Apr 2012
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of reveglucosidase alfa in Pompe disease, sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Primary objectives (unspecified clinical and safety outcomes). Started Apr 2012; status: completed.
02
Drugs
reveglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on 2011-001805-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001805-28.